Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Conditions: Gastrointestinal Stromal Tumors Interventions: Drug: Regorafenib Sponsors: M.D. Anderson Cancer Center; Bayer Not yet recruiting

Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials